Curative Biotechnology Stock Current Liabilities
| CUBT Stock | USD 0.01 0.0004 2.99% |
Curative Biotechnology fundamentals help investors to digest information that contributes to Curative Biotechnology's financial success or failures. It also enables traders to predict the movement of Curative Stock. The fundamental analysis module provides a way to measure Curative Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Curative Biotechnology stock.
Total Current Liabilities is likely to gain to about 6.9 M in 2025. Non Current Liabilities Total is likely to gain to about 21.9 M in 2025. Curative | Current Liabilities |
Curative Biotechnology Company Current Liabilities Analysis
Curative Biotechnology's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Curative Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Curative Biotechnology is extremely important. It helps to project a fair market value of Curative Stock properly, considering its historical fundamentals such as Current Liabilities. Since Curative Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Curative Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Curative Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Curative Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Curative Biotechnology has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Curative Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Curative Biotechnology's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Curative Biotechnology could also be used in its relative valuation, which is a method of valuing Curative Biotechnology by comparing valuation metrics of similar companies.Curative Biotechnology is currently under evaluation in current liabilities category among its peers.
Curative Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Curative Biotechnology from analyzing Curative Biotechnology's financial statements. These drivers represent accounts that assess Curative Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Curative Biotechnology's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 9.9M | 26.1M | 11.4M | 14.1M | 12.7M | 13.3M | |
| Enterprise Value | 10.3M | 25.4M | 12.5M | 16.3M | 14.7M | 15.4M |
Curative Fundamentals
| Return On Equity | -3.98 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 13.01 M | ||||
| Shares Outstanding | 903.26 M | ||||
| Shares Owned By Insiders | 0.05 % | ||||
| Price To Sales | 158.53 X | ||||
| Revenue | 132.32 K | ||||
| Gross Profit | 100.21 K | ||||
| EBITDA | (2.5 M) | ||||
| Net Income | (3.96 M) | ||||
| Cash And Equivalents | 126.85 K | ||||
| Total Debt | 2.26 M | ||||
| Debt To Equity | 6.60 % | ||||
| Current Ratio | 0.10 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (486.58 K) | ||||
| Earnings Per Share | (0.01) X | ||||
| Beta | 214.95 | ||||
| Market Capitalization | 11.74 M | ||||
| Total Asset | 2.6 M | ||||
| Retained Earnings | (38.23 M) | ||||
| Working Capital | (4.42 M) | ||||
| Net Asset | 2.6 M |
About Curative Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Curative Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Curative Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Curative Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.